aTyr Pharma (NASDAQ:ATYR) Stock Rating Upgraded by Wall Street Zen

aTyr Pharma (NASDAQ:ATYR) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

A number of other research firms have also recently commented on ATYR. Jefferies Financial Group reiterated a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $25.67.

aTyr Pharma Trading Up 5.2%

Shares of ATYR opened at $0.89 on Friday. The stock has a 50 day moving average of $0.86 and a 200 day moving average of $1.20. The company has a market capitalization of $87.71 million, a price-to-earnings ratio of -1.13 and a beta of 0.55. aTyr Pharma has a 12 month low of $0.64 and a 12 month high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. As a group, equities research analysts predict that aTyr Pharma will post -0.91 earnings per share for the current year.

Institutional Trading of aTyr Pharma

A number of institutional investors have recently modified their holdings of ATYR. Profund Advisors LLC bought a new position in aTyr Pharma in the 3rd quarter worth approximately $27,000. California State Teachers Retirement System bought a new stake in aTyr Pharma during the 2nd quarter valued at $28,000. ADAR1 Capital Management LLC raised its holdings in aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock valued at $40,000 after acquiring an additional 13,385 shares during the period. Kingswood Wealth Advisors LLC purchased a new stake in shares of aTyr Pharma during the fourth quarter worth $41,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in shares of aTyr Pharma during the second quarter worth $45,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.